FRIDAY, JULY 21, 2017

Cholera spreads through refugee camps in Nigeria

Borno State health authorities and Doctors Without Borders (MSF) have been working with logistics and emergency medical services to stop the spread of cholera throughout the internally displaced persons camps in Borno State, Nigeria. Read More »

World Molecular Imaging Congress focuses on HuMab 5B1 antibody

MabVax Therapeutics Holdings Inc., a clinical stage oncology drug development company, recently announced that its top antibody, HuMab 5B1, will be the main focus at the World Molecular Imaging Congress (WMIC). Read More »

Flu vaccines prove sensible for elderly

A recent study shows that the influenza vaccination is especially valuable for the elderly population. Read More »

Pfizer receives clearance to acquire Hospira

Pharmaceutical company must divest itself of four U.S. sterile injectable assets before deal is done. Read More »

Genetic expression allows scientist to grow hepatitis C in lab

A team of researchers recently discovered that an overexpression within a specific gene found in human liver cancer cell lines allows them to grow hepatitis C easily in their labs. Read More »

Research shows why children with malaria often develop deadly blood cancer

A team of scientists from Rockefeller University recently conducted research to explain how malaria infections can increase the chances that a child will develop a deadly, aggressive blood cancer called Burkitt’s lymphoma. Read More »

Novartis Foundation holds meeting to discuss leprosy elimination

The Novartis Foundation recently called together professionals from the anti-leprosy community and the global health community to discuss current leprosy care and treatment and the future possibility of eliminating leprosy. Read More »

Over 287,000 children vaccinated for measles in the Democratic Republic of the Congo

Medecins Sans Frontieres (MSF), or Doctors Without Borders, recently announced that it has successfully vaccinated more than 287,000 children for measles in the Democratic Republic of the Congo (DRC) since March. Read More »

Novartis completes influenza vaccine business divestiture to CSL Limited

Novartis announced today that it has finished its divestiture of the company’s influenza vaccine unit to another company, CSL Limited, for $275 million (USD). Read More »

Computer model successfully predicts flu outbreaks in subtropical climates

A team of scientists, from Columbia University’s Mailman School of Public Health and the University of Hong Kong’s School of Public Health of Li Ka Shing Faculty of Medicine, recently demonstrated a computer model that can predict influenza outbreaks within subtropical climates. Read More »

Antibodies targeting host proteins efficient against malaria, study says

A new study published Monday in the Journal of Experimental Medicine suggests that malaria drugs that target the proteins of the host may be useful for a variety of novel interventions for the illness. Read More »

Study shows new drug effectively blocks malaria

An innovative drug effectively blockades the body against malaria parasites, which may prove to be a new cure for the illness, a study in The Journal of Experimental Medicine said Monday. Read More »

WHO gives prequalification status to Coartem malaria treatment

The World Health Organization (WHO) granted prequalification status Thursday to Coartem 80/480 mg, a malaria treatment created by Novartis, giving better access to patients. Coartem is the first fixed-dose, high strength artemisinin-based combination therapy (ACT) antimalarial treatment and also the first child-friendly ACT Read More »

Pfizer launches Phase 2b trial of multi-antigen Staphylococcus aureus vaccine

Pfizer, Inc. said Tuesday it has enrolled its first patient in the company’s Phase 2b clinical trial for its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (P-06290510) for adults having elective spinal fusion surgery. Read More »

Discovery advances quest for a universal flu vaccine

Scientists from Rockefeller University said they have found a new mechanism in the immune system that could lead to more efficient and accurate universal flu vaccines. Read More »

Bristol-Myers Squibb committed to boosting research presence, impact

Bristol-Myers Squibb said this week that it has taken the next steps in expanding its research-and-development unit to facilitate world-class innovations and breakthroughs. The company is building a new state-of-the-art research facility in Cambridge, Massachusetts, and has been expanding another facility in the San Francisco Bay Area. Read More »

Global Healthy Living Foundation recommends Meningitis B vaccines

Dr. Neal Raisman, an ambassador from the Global Healthy Living Foundation, along with other vaccine advocates throughout the U.S., encouraged the Centers for Disease Control and Prevention (CDC) panel to recommend Meningitis B vaccines. Read More »

Pfizer to buy meningitis vaccines from GlaxoSmithKline

Pfizer Inc. recently announced that it has made an agreement with GlaxoSmithKline to acquire Nimenrix and Mencevax vaccines for meningitis A, C, W135 and Y. Read More »

Novartis holds workshop to help eliminate malaria in Africa

Novartis said Friday it recently held the 14th annual National Malaria Control Program (NMCP) Best Practice Sharing Workshop in Mozambique in order to encourage African nations to eliminate malaria.Africa currently faces a major turning point in battling malaria. The three-day workshop was called in order for malaria experts from more than 35 African countries to exchange and discuss innovative strategies and tools to eliminate malaria. Read More »

Meningitis vaccine shortages are critical in Niger

A meningitis vaccine shortage has jeopardized the fight against meningitis in Niger, where more than 6,000 suspected meningitis cases and 443 deaths related to meningitis have occurred in the past three months. Read More »